Pfenex Inc. Daily Stock Analysis

Daily Stock Analysis, PFNX, Pfenex Inc, priceseries

Pfenex Inc. Daily Stock Analysis
Stock Information
Open
12.74
Close
12.75
High
12.94
Low
12.74
Previous Close
12.76
Daily Price Gain
-0.01
YTD High
24.41
YTD High Date
Jul 16, 2015
YTD Low
2.07
YTD Low Date
Dec 18, 2017
YTD Price Change
7.45
YTD Gain
140.57%
52 Week High
24.41
52 Week High Date
Jul 16, 2015
52 Week Low
2.07
52 Week Low Date
Dec 18, 2017
52 Week Price Change
7.45
52 Week Gain
140.57%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 2. 2018
2.77
Jan 18. 2018
3.10
11 Trading Days
11.94%
Link
LONG
Mar 20. 2018
5.15
Apr 2. 2018
5.66
8 Trading Days
9.81%
Link
LONG
Feb 27. 2019
4.18
Mar 6. 2019
4.42
5 Trading Days
5.86%
Link
LONG
Mar 19. 2019
5.10
Apr 2. 2019
5.82
10 Trading Days
14.03%
Link
LONG
May 8. 2019
5.75
May 29. 2019
6.73
14 Trading Days
16.98%
Link
LONG
Aug 26. 2019
6.95
Sep 20. 2019
9.01
18 Trading Days
29.71%
Link
LONG
Nov 25. 2019
9.68
Dec 26. 2019
12.09
21 Trading Days
24.94%
Link
LONG
Jun 12. 2020
9.05
Jun 16. 2020
9.70
2 Trading Days
7.18%
Link
Company Information
Stock Symbol
PFNX
Exchange
NYSE MKT
Company URL
http://www.pfenex.com
Company Phone
858-352-4400
CEO
Patrick K. Lucy
Headquarters
California
Business Address
10790 ROSELLE STREET, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001478121
About

Pfênex, Inc. is a clinical-stage biotechnology company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes biosimilars and vaccines. The company was founded on November 19, 2009 and is headquartered in San Diego, CA.

Description

Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. Its lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; PF582, a biosimilar to Lucentis (ranibizumab) for the treatment of patients with retinal diseases; and Px563L, a novel anthrax vaccine candidate in Phase 1a trial. The company also engages in developing a pipeline of additional biosimilar candidates, including PF529, a biosimilar candidate to Neulasta; PF688, a biosimilar candidate to Cimzia; PF530, a biosimilar candidate to Betaseron; PF690, a biosimilar candidate to the reference product Oncaspar; PF444-human growth hormone, a biosimilar candidate to Genotropin; and PF688-certolizumab-pegol, a biosimilar candidate to Cimzia. It has collaboration agreements with Hospira, Inc. and Jazz Pharmaceuticals Ireland Limited. Pfenex Inc. is headquartered in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading